NK cells adjuvant therapy shows survival benefits in a gastric mixed signet ring cell carcinoma patient: A case report

Medicine (Baltimore). 2021 Mar 12;100(10):e24979. doi: 10.1097/MD.0000000000024979.

Abstract

Rationale: Advanced signet ring cell (SRC) carcinoma has a worse prognosis. Therefore, early diagnosis and prevention is particularly important; SRC tumors have lower R0 resection rate and are thought to be less chemosensitive than non-SRCC. Consequently, a novel postoperative adjuvant treatment is urgently needed to improve clinical outcomes.

Patient concerns: A 41-year-old female with advanced gastric SRC carcinoma was treated with radical gastrectomy and oxaliplatin-based regimen for 6 cycles after surgery. She was suspected of recurrence with the high level of carbohydrate antigen (CA) 72-4.

Diagnoses: The gastroscopy revealed SRC carcinoma of gastric antrum and poorly differentiated adenocarcinoma in some areas. The diagnosis of postoperative pathology report was gastric cancer with stage III C (T4a, N3a, M0).

Interventions: The level of CA72-4 rapidly increased during the 2 follow-up after the completion of conventional treatment, ex vivo-cultured allogeneic natural killer (NK) cell infusion was offered to prevent recurrence.

Outcomes: Intravenous injections of NK cells combination with surgical treatment and chemotherapy showed therapeutic effects in this patient with possible relapse. The patient remained disease-free 46 months after the infusion of NK cells until the latest follow-up.

Lessons: CA72-4 appeared to be the most sensitive and specific marker in the gastric cancer patient, and the high level of CA72-4 may indicate the risk of recurrence. This case report provide rationale for NK cell infusion following the rapid increase of CA72-4 to prevent recurrence.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antigens, Tumor-Associated, Carbohydrate / blood
  • Antigens, Tumor-Associated, Carbohydrate / immunology
  • Carcinoma, Signet Ring Cell / diagnosis
  • Carcinoma, Signet Ring Cell / immunology
  • Carcinoma, Signet Ring Cell / pathology
  • Carcinoma, Signet Ring Cell / therapy*
  • Combined Modality Therapy / methods
  • Female
  • Gastrectomy*
  • Humans
  • Killer Cells, Natural / transplantation*
  • Neoplasm Staging
  • Postoperative Care / methods*
  • Prognosis
  • Stomach Neoplasms / diagnosis
  • Stomach Neoplasms / immunology
  • Stomach Neoplasms / pathology
  • Stomach Neoplasms / therapy*
  • Transplantation, Homologous
  • Treatment Outcome

Substances

  • Antigens, Tumor-Associated, Carbohydrate
  • CA-72-4 antigen